Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shun-Ichi Wakabayashi

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Biomedicines|March 28, 2026
Network Biology and Translational Strategies in Liver FibrosisTakefumi Kimura, Takanobu Iwadare, Shun-Ichi Wakabayashi
Journal of Gastroenterology|April 3, 2024
Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver diseaseShun-Ichi Wakabayashi, Nobuharu Tamaki, Takefumi Kimura, et al.
Japanese Journal of Radiology|January 27, 2026
Metabolic dysfunction-associated steatotic liver disease (MASLD): definition, diagnosis, natural history, and treatmentNobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, et al.
Medicina (Kaunas, Lithuania)|April 3, 2021
Primary Hepatic Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in a Patient with Chronic Hepatitis B Virus Infection: Case Report and Summary of the LiteratureYuki Yamashita, Satoru Joshita, Hiroyuki Kobayashi, et al.
Alimentary Pharmacology & Therapeutics|November 15, 2025
Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD, MetALD and ALDNobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, et al.
Alimentary Pharmacology & Therapeutics|August 8, 2024
Cardiometabolic criteria as predictors and treatment targets of liver-related events and cardiovascular events in metabolic dysfunction-associated steatotic liver diseaseNobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, et al.
Alimentary Pharmacology & Therapeutics|April 26, 2024
Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortalityNobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 1, 2025
Colorectal Cancer Incidence in Steatotic Liver Disease (MASLD, MetALD, and ALD)Takefumi Kimura, Nobuharu Tamaki, Shun-Ichi Wakabayashi, et al.
Cancers|July 2, 2021
Investigation of the Effect of KIR-HLA Pairs on Hepatocellular Carcinoma in Hepatitis C Virus Cirrhotic PatientsTakeji Umemura, Satoru Joshita, Hiromi Saito, et al.
Journal of Viral Hepatitis|June 26, 2023
Kinetics of serum O-glycosylated M-hepatitis B surface antigen with hepatocellular carcinoma history and nucleos(t)ide analogue therapy in hepatitis B patientsTaiki Okumura, Satoru Joshita, Takanobu Iwadare, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Biomedicines|March 28, 2026
Network Biology and Translational Strategies in Liver FibrosisTakefumi Kimura, Takanobu Iwadare, Shun-Ichi Wakabayashi
Journal of Gastroenterology|April 3, 2024
Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver diseaseShun-Ichi Wakabayashi, Nobuharu Tamaki, Takefumi Kimura, et al.
Japanese Journal of Radiology|January 27, 2026
Metabolic dysfunction-associated steatotic liver disease (MASLD): definition, diagnosis, natural history, and treatmentNobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, et al.
Medicina (Kaunas, Lithuania)|April 3, 2021
Primary Hepatic Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in a Patient with Chronic Hepatitis B Virus Infection: Case Report and Summary of the LiteratureYuki Yamashita, Satoru Joshita, Hiroyuki Kobayashi, et al.
Alimentary Pharmacology & Therapeutics|November 15, 2025
Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD, MetALD and ALDNobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, et al.
Alimentary Pharmacology & Therapeutics|August 8, 2024
Cardiometabolic criteria as predictors and treatment targets of liver-related events and cardiovascular events in metabolic dysfunction-associated steatotic liver diseaseNobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, et al.
Alimentary Pharmacology & Therapeutics|April 26, 2024
Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortalityNobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 1, 2025
Colorectal Cancer Incidence in Steatotic Liver Disease (MASLD, MetALD, and ALD)Takefumi Kimura, Nobuharu Tamaki, Shun-Ichi Wakabayashi, et al.
Cancers|July 2, 2021
Investigation of the Effect of KIR-HLA Pairs on Hepatocellular Carcinoma in Hepatitis C Virus Cirrhotic PatientsTakeji Umemura, Satoru Joshita, Hiromi Saito, et al.
Journal of Viral Hepatitis|June 26, 2023
Kinetics of serum O-glycosylated M-hepatitis B surface antigen with hepatocellular carcinoma history and nucleos(t)ide analogue therapy in hepatitis B patientsTaiki Okumura, Satoru Joshita, Takanobu Iwadare, et al.
Pageof 4